Pharmacological protection from radiation ± cisplatin-induced oral mucositis.

@article{Cotrim2012PharmacologicalPF,
  title={Pharmacological protection from radiation ± cisplatin-induced oral mucositis.},
  author={Ana P. Cotrim and Masanobu Yoshikawa and Abraham N Sunshine and Changyu Zheng and Anastasia L. Sowers and Angela Thetford and John A. Cook and James B. Mitchell and B J Baum},
  journal={International journal of radiation oncology, biology, physics},
  year={2012},
  volume={83 4},
  pages={
          1284-90
        }
}
PURPOSE To evaluate if two pharmacological agents, Tempol and D-methionine (D-met), are able to prevent oral mucositis in mice after exposure to ionizing radiation ± cisplatin. METHODS AND MATERIALS Female C3H mice, ∼8 weeks old, were irradiated with five fractionated doses ± cisplatin to induce oral mucositis (lingual ulcers). Just before irradiation and chemotherapy, mice were treated, either alone or in combination, with different doses of Tempol (by intraperitoneal [ip] injection or… Expand
Bone Marrow–derived Cell Therapy for Oral Mucosal Repair after Irradiation
TLDR
Findings suggest that exogenous BMDCs behave to reduce radiogenic oral mucositis in a paracrine manner. Expand
A Mouse Model for Oral Mucositis Induced by Cancer Chemotherapy.
TLDR
A mouse model of OM induced by cancer chemotherapy is developed and is expected to contribute to development of new drugs and elucidation of the mechanisms of ameliorating stomatitis as a side-effect of anticancer drugs. Expand
Gene Therapy for Mucositis
TLDR
Reduction of irradiation-induced oral cavity and oropharyngeal mucositis should allow dose escalation in clinical trials of chemoradiotherapy and biological response modifier therapy of head and neck cancers, but more importantly, reduce significant side effects of treatment. Expand
Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.
TLDR
The safety ofGC4419 concurrently with chemoradiation for OCC was acceptable and the potential of GC4419 to reduce severe oral mucositis seemed less frequent and briefer than expected. Expand
Adipose mesenchymal stromal cells minimize and repair radiation-induced oral mucositis.
TLDR
Syngenic freshly cultured aMSCs significantly minimized and repaired radiation-induced oral mucositis with a 72% reduction in ulcer duration and dose size and frequency, number of doses and therapy onset time are the main keys for optimized therapeutic outcome. Expand
Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis
TLDR
New molecular mechanisms involved in oral mucositis pathogenesis are identified, and data suggest an alternative therapeutic strategy to block multiple pathological processes in this condition. Expand
Antioxidant agents: a future alternative approach in the prevention and treatment of radiation-induced oral mucositis?
TLDR
It is shown that the research on use of antioxidants (AOX) has proved insufficient to justify suggesting the products in treatment protocols, and results are promising, however, and AOX may represent a future alternative in the prevention and treatment of oral mucositis. Expand
Topical application of Aloe vera and vitamin E on induced ulcers on the tongue of rats subjected to radiation: clinical and histological evaluation
TLDR
It is suggested that VE and AV contributed to the decrease in inflammatory response and healing of the lesions induced on the tongue of rats subjected to radiation. Expand
Double‐blind placebo‐controlled multicenter phase II trial to evaluate D‐methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer
TLDR
Results of multiple assessments suggest that D-met decreased mucositis during chemoradiotherapy, although not meeting the primary end point. Expand
Radiation protection from whole-body gamma irradiation (6.7 Gy): behavioural effects and brain protein-level changes by an aminothiol compound GL2011 in the Wistar rat
TLDR
The findings demonstrate that GL2011 improves survival rates and jejunal crypt survival, provides partial neuroprotection at the behavioural level and modulates proteins known to be involved in protection against oxidative stress-mediated cell damage. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 22 REFERENCES
Evaluation of d-Methionine as a Novel Oral Radiation Protector for Prevention of Mucositis
TLDR
d-Met protected normal tissues, but not tumor cells, in culture from radiation-induced cell death; it also protected normal cells from Radiation-induced mucosal injury in a murine model but did not alter tumor response to therapy. Expand
Kinetics of Tempol for Prevention of Xerostomia Following Head and Neck Irradiation in a Mouse Model
TLDR
The results strongly suggest that tempol is a promising candidate for clinical application to protect salivary glands in patients undergoing radiotherapy for head and neck cancers. Expand
Palifermin for oral mucositis after intensive therapy for hematologic cancers.
TLDR
Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers. Expand
Evaluation of tempol radioprotection in a murine tumor model.
TLDR
The differences in radioprotection may result from enhanced intratumor bioreduction of Tempol to its nonradioprotective hydroxylamine analogue, which may provide a means to exploit the redox differences between normal tissues and tumors. Expand
Prevention of Radiation-Induced Oral Mucositis after Adenoviral Vector–Mediated Transfer of the Keratinocyte Growth Factor cDNA to Mouse Submandibular Glands
TLDR
This proof of concept study suggests that transgenic hKGF secreted from transduced salivary glands may be useful clinically to prevent oral mucositis caused by radiation. Expand
A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
TLDR
This study demonstrates that topical application of Tempol to the scalp before whole brain radiation is safe and well tolerated and evidence of protection against radiation-induced alopecia was observed. Expand
Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging
TLDR
Data support further development and consideration of Tempol for human clinical trials as a selective protector against radiation-induced salivary gland damage and also support the hypothesis that differential radioprotection by Tempol resides in faster reduction to the nonradioprotective hydroxylamine in tumor compared with normal tissues. Expand
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis
TLDR
Evaluated evidence supporting the use of palifermin in autologous HSCT recipients with hematologic malignancies is clear, and some data exist demonstrating its efficacy in other oncologic indications. Expand
Mucositis: The impact, biology and therapeutic opportunities of oral mucositis.
TLDR
Current research is leading to a comprehensive understanding of the biology of mucositis, which has resulted in the development of novel interventions and a number of eclectic molecules, all designed to interfere with pathways that lead to injury are in pre-clinical and clinical development. Expand
Pharmacokinetic Analysis and Phase 1 Study of MRX-1024 in Patients Treated with Radiation Therapy with or without Cisplatinum for Head and Neck Cancer
TLDR
There is a dose-dependent increase in D-met exposure following MRx-1024 administration at 50 and 100 mg/kg, and MRX-1024 is safe for use concurrent with combined radiation and chemotherapy. Expand
...
1
2
3
...